112 related articles for article (PubMed ID: 19808128)
1. Neutralization of alpha(2)-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers.
Pakola S; Cahillane G; Stassen JM; Lijnen HR; Verhamme P
Clin Ther; 2009 Aug; 31(8):1688-706. PubMed ID: 19808128
[TBL] [Abstract][Full Text] [Related]
2. Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke.
Thijs VN; Peeters A; Vosko M; Aichner F; Schellinger PD; Schneider D; Neumann-Haefelin T; Röther J; Davalos A; Wahlgren N; Verhamme P
Stroke; 2009 Dec; 40(12):3789-95. PubMed ID: 19834019
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
[TBL] [Abstract][Full Text] [Related]
4. Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.
Dommke C; Turschner O; Stassen JM; Van de Werf F; Lijnen HR; Verhamme P
J Thromb Thrombolysis; 2010 Jul; 30(1):46-54. PubMed ID: 19834783
[TBL] [Abstract][Full Text] [Related]
5. A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy.
Benz MS; Packo KH; Gonzalez V; Pakola S; Bezner D; Haller JA; Schwartz SD
Ophthalmology; 2010 Apr; 117(4):791-7. PubMed ID: 20138368
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
Rosenberg G; Angel I; Kozak A
Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
10. A Bolus and Bolus Followed by Infusion Study of AZD3043, an Investigational Intravenous Drug for Sedation and Anesthesia: Safety and Pharmacodynamics in Healthy Male and Female Volunteers.
Norberg Å; Koch P; Kanes SJ; Björnsson MA; Barassin S; Ahlén K; Kalman S
Anesth Analg; 2015 Oct; 121(4):894-903. PubMed ID: 26097986
[TBL] [Abstract][Full Text] [Related]
11. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal injection of microplasmin for treatment of vitreomacular adhesion: results of a prospective, randomized, sham-controlled phase II trial (the MIVI-IIT trial).
Stalmans P; Delaey C; de Smet MD; van Dijkman E; Pakola S
Retina; 2010; 30(7):1122-7. PubMed ID: 20616687
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
14. Catheter-directed thrombolysis with microplasmin for acute peripheral arterial occlusion (PAO): an exploratory study.
Verhamme P; Heye S; Peerlinck K; Cahillane G; Tangelder M; Fourneau I; Daenens K; Belmans A; Pakola S; Verhaeghe R; Maleux G
Int Angiol; 2012 Jun; 31(3):289-96. PubMed ID: 22634985
[TBL] [Abstract][Full Text] [Related]
15. A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis.
Verhamme P; Jerome M; Goossens G; Devis J; Maleux G; Stas M
J Thromb Thrombolysis; 2009 Nov; 28(4):477-81. PubMed ID: 19225865
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: A randomized, double-blind, placebo-controlled, ascending-dose study.
Chen Q; Hu C; Liu Y; Liu Y; Wang W; Zheng H; Rong L; Jia J; Sun S; Yu C; Liu YM
PLoS One; 2017; 12(5):e0177425. PubMed ID: 28493932
[TBL] [Abstract][Full Text] [Related]
17. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.
Lapchak PA; Araujo DM; Pakola S; Song D; Wei J; Zivin JA
Stroke; 2002 Sep; 33(9):2279-84. PubMed ID: 12215599
[TBL] [Abstract][Full Text] [Related]
18. Psychomotor performance in healthy young adult volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover trial.
Fabbrini M; Frittelli C; Bonanni E; Maestri M; Manca ML; Iudice A
Clin Ther; 2005 Jan; 27(1):78-83. PubMed ID: 15763608
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
20. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
